McKesson (MCK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Jun, 2026Executive summary
Proxy statement filed for annual meeting, outlining key proposals and governance matters.
Voting matters and shareholder proposals
Shareholders are asked to vote on various proposals, including board elections and other corporate actions.
Board of directors and corporate governance
Details provided regarding board composition and governance practices for the upcoming year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from McKesson
- Revenue up 21%, Adjusted EPS up 13%, 2025 guidance raised, $2.2B returned to shareholders.MCK
Q2 20258 Jul 2026 - Raised FY26 EPS guidance, specialty growth, and segment separation drive long-term value.MCKInvestor Day 20258 Jul 2026
- Adjusted EPS up 8% on 6% revenue growth; guidance, dividend, and buyback all raised.MCKQ1 20258 Jul 2026
- Key votes include board elections, auditor ratification, and executive pay approval.MCKProxy filing12 Jun 2026
- Proxy details strong financials, board refreshment, and robust pay-for-performance alignment.MCKProxy filing12 Jun 2026
- Specialty drugs, biosimilars, and automation drive growth and margin expansion into 2027.MCKBank of America Global Healthcare Conference 202612 May 2026
- FY26 delivered double-digit revenue and EPS growth, with robust FY27 outlook and portfolio optimization.MCKQ4 20268 May 2026
- Revenue up 11%, adjusted EPS up 16%, and fiscal 2026 EPS guidance raised to $38.80–$39.20.MCKQ3 202613 Apr 2026
- Strong growth in core segments and technology, with MedSurg spin-off planned for 2027.MCKBarclays 28th Annual Global Healthcare Conference12 Mar 2026